Balboa Wealth Partners Halozyme Therapeutics, Inc. Transaction History
Balboa Wealth Partners
- $398 Million
- Q1 2025
A detailed history of Balboa Wealth Partners transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Balboa Wealth Partners holds 5,635 shares of HALO stock, worth $275,833. This represents 0.09% of its overall portfolio holdings.
Number of Shares
5,635
Previous 6,175
8.74%
Holding current value
$275,833
Previous $295,000
21.69%
% of portfolio
0.09%
Previous 0.07%
Shares
5 transactions
Others Institutions Holding HALO
# of Institutions
587Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$862 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$628 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$296 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$191 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$180 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.82B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...